Cargando…

Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19

BACKGROUND: Due to the latent onset of novel coronavirus disease 2019 (COVID-19), it is important to identify patients with increased probabilities for disease progression early in order to implement timely medical strategies. This study aimed to identify the factors associated with increased COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Xiaowei, Kang, Shiwei, Guo, Xianfeng, Li, Yan, Gao, Haixiang, Yuan, Yadong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190755/ https://www.ncbi.nlm.nih.gov/pubmed/34112084 http://dx.doi.org/10.1186/s12879-021-06282-6

Ejemplares similares

Association of smoking and cardiovascular disease with disease progression in COVID-19: a systematic review and meta-analysis
por: Kang, Shiwei, et al.
Publicado: (2021)

A Nomogram for Predicting the Risk of Pulmonary Hypertension for Patients with Chronic Obstructive Pulmonary Disease
por: Wang, Ning, et al.
Publicado: (2022)

Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis
por: Gong, Xiaowei, et al.
Publicado: (2022)

COVID-19: Risk factors for critical illness
por: Gao, Yadong
Publicado: (2020)

Stroke risk of COPD patients and death risk of COPD patients following a stroke: A systematic review and meta-analysis
por: Ding, Chaowei, et al.
Publicado: (2023)

Improvement of Severe COVID-19 in an Elderly Man by Sequential Use of Antiviral Drugs
por: Yatomi, Masakiyo, et al.
Publicado: (2020)

Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19
por: Panda, Prasan Kumar, et al.
Publicado: (2021)

Risk Factors and Drug Efficacy for Severe Illness in Hemodialysis Patients Infected with the Omicron Variant of COVID-19
por: Wu, Yan, et al.
Publicado: (2023)

Antiviral Therapy of COVID-19
por: Gudima, Georgii, et al.
Publicado: (2023)

Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
por: Esposito, Renata, et al.
Publicado: (2022)

Development of antiviral therapy for severe acute respiratory syndrome
por: Cinatl, Jindrich, et al.
Publicado: (2005)

Antiviral Drugs
por: Vardanyan, Ruben, et al.
Publicado: (2016)

Antiviral drugs
por: Koch, Oliver, et al.
Publicado: (2010)

Antiviral drugs
por: Samuel, Essie, et al.
Publicado: (2022)

Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study
por: Yin, Peng, et al.
Publicado: (2021)

Coronavirus main proteinase: target for antiviral drug therapy
por: Anand, Kanchan, et al.
Publicado: (2005)

Antiviral therapy and immunotherapy of COVID-19
por: Crespillo, Clara, et al.
Publicado: (2021)

Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy
por: Batool, Sania, et al.
Publicado: (2023)

Association between diabetes and venous thromboembolism: A systematic review and meta-analysis
por: Ding, Chaowei, et al.
Publicado: (2023)

Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection
por: Takayama-Ito, Mutsuyo, et al.
Publicado: (2020)

Broad-Spectrum Antivirals and Antiviral Drug Combinations
por: Oksenych, Valentyn, et al.
Publicado: (2022)

Current and future antiviral therapy of severe seasonal and avian influenza
por: Beigel, John, et al.
Publicado: (2008)

Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure)
por: Ning, Qin, et al.
Publicado: (2019)

Sars-Cov-2 and risk of antiviral drug resistance
por: Vitiello, Antonio
Publicado: (2021)

Pregnancy-related Kasabach–Merritt phenomenon with pleural effusion: A case report and literature review
por: Jiao, Xiaodan, et al.
Publicado: (2022)

The combined regimens of antiviral therapy might not be useful for the viral clearance of severe COVID-19 cases
por: Li, Xuan, et al.
Publicado: (2021)

Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial
por: Gong, Xiaowei, et al.
Publicado: (2021)

Modelling the evolution of drug resistance in the presence of antiviral drugs
por: Wu, Jianhong, et al.
Publicado: (2007)

The Antiviral Drug Efavirenz in Breast Cancer Stem Cell Therapy
por: Chiou, Pey-Tsyr, et al.
Publicado: (2021)

Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study
por: Liu, Xia, et al.
Publicado: (2023)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
por: Pei, Haixiang, et al.
Publicado: (2019)

Antiviral drug resistance /
Publicado: (1996)

Antiviral Drugs for EBV
por: Pagano, Joseph S., et al.
Publicado: (2018)

Antiviral and Immunomodulatory Drugs
por: Sykes, Jane E., et al.
Publicado: (2014)

Antiviral Drugs in Influenza
por: Świerczyńska, Magdalena, et al.
Publicado: (2022)

Metabolomics to Predict Antiviral Drug Efficacy in COVID-19
por: Migaud, Marie, et al.
Publicado: (2020)

Antiviral Drug Discovery To Address the COVID-19 Pandemic
por: Richman, Douglas D.
Publicado: (2020)

Use of antiviral drugs to reduce COVID-19 transmission
por: Mitjà, Oriol, et al.
Publicado: (2020)

Scoping insight on antiviral drugs against COVID-19
por: Ali, Ahmed S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1aavkhl14v9kniah4dmb1jvdvh